AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2021
Sep 17, 2021
31920_dirs_2021-09-17_d958d969-7338-4b57-8a75-bc54bb7a36bf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2021-09-16
Reporting Person: Glass Geoffrey Michael (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-16 | Stock Option (Right to Buy) | $8.07 | G | 42000 | Disposed | 2031-08-03 | ADSs (42000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $8.07 | 2031-08-03 | ADSs (42000) | 42000 | Indirect |
Footnotes
F1: Options shall vest in full on the earlier to occur of (a) August 3, 2022 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.
F2: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
F3: On September 16, 2021, the reporting person transferred 42,000 options to a family trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.